Congestive heart failure (Generic Accupril is used for lowering high blood pressure and managing heart failure) is a major public health problem affecting over 4.7 million Americans and 15 million people worldwide. More than 550,000 new cases occur annually in the United States. Approximately 1.5-2% of the population has CHF, and the prevalence increases to 6-10% in patients 65 years and over. CHF (Altace drug is used to treat of heart failure and hypertension) is a major cause of morbidity and mortality among older people in Western countries. It is the leading indication for hospital admission in adults older than age 65. Among factors related to rehospitalization are non-adherence to medication and advice on lifestyle modifications, as well as failure to seek medical attention when the condition deteriorates. Despite advances in pharmacological treatment, the prognosis of older patients hospitalized for heart failure (Lanoxin 250 mg is used for treating heart failure) is poor, with one-month posthospitalization mortality exceeding 25% and one-year mortality greater than 50% in persons age 85 years and above.
Although normal aging is not necessarily associated with diminished cognitive function, up to 17% of those aged 65 years and older do experience at least mild-to-moderate decreases in cognitive function, especially those related to memory, which are not related to dementia of either the vascular or Alzheimer’s type. Cognitive impairment is rapidly becoming a public health problem, and it shows a strong association with dependency, morbidity and mortality.
Decrease in cognitive function has been reported in patients with a variety of cardiovascular conditions. There is increasing evidence that CHF (Generic Lozol treating high blood pressure, swelling, or congestive heart failure) is independently associated with cognitive impairment. “Cardiogenic” or “circulatory” dementia has been proposed to explain cognitive impairment in these patients. CHF (diovan 80 mg is used to treat high blood pressure and heart failure) and cognitive impairment are both associated with increased mortality, disability, decreased quality of life and spousal and caregiver distress.
Our search of the medical literature highlighted the paucity of data on the prevalence of cognitive impairment among CHF (Canadian Aldactone is used for treating swelling and fluid retention inpatients with congestive heart failure) patients, especially in the African-American population. The above-referenced study indicated that African Americans were found to go home much sicker, more dependent and more cogni-tively impaired than their white counterparts. Because CHF (Aldactone 25 mg treating swelling and fluid retention inpatients with congestive heart failure) disproportionately affects African Americans and the incidence and prevalence of this disease is higher in this population of patients than other racial groups, the high prevalence of cognitive impairment among this group of patients could have clinical and public health implications. Therefore, the present study sought to assess the prevalence of cognitive impairment among African-American patients with CHF (Diovan canadian used for treating heart failure).